Device Trial Radar · NCT03729453
Intra-operative Pancreatoscopy in Patients With IPMN
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Actual
Start
Mar 20, 2019
Primary completion
Aug 11, 2022
Study completion May 2027
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Nov 2, 2018
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the added value of intraoperative pancreatoscopy in patients undergoing partial pancreatic resection for the treatment of Intraductal Papillary Mucinous Neoplasm (IPMN) as it pertains to detection of discontinuous (skip) lesions in the remnant pancreas; to generate a hypothesis for a subsequent randomized control trial.
Conditions
- Intraductal Papillary Mucinous Neoplasm
Interventions
SpyGlassDevice
Visualization of main pancreatic duct with SpyGlass catheter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of detection of discontinuous (skip) lesions along the main pancreatic ductTime frame: During index procedure
Locations
8 sites in 6 countries. Site status is shown where the registry gives one.
University of Colorado Hospital
Denver, Colorado
Indiana University Health
Indianapolis, Indiana
Johns Hopkins Hospital University
Baltimore, Maryland
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.